These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17359908)

  • 1. CD117 (c-kit) expression in human hepatocellular carcinoma.
    Becker G; Schmitt-Graeff A; Ertelt V; Blum HE; Allgaier HP
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):204-8. PubMed ID: 17359908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?
    Kara B; Doran F; Kara IO; Akkiz H; Sandikci M
    Int J Clin Pract; 2008 Aug; 62(8):1206-11. PubMed ID: 18284441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.
    Eckel F; von Delius S; Mayr M; Dobritz M; Fend F; Hosius C; Schleyer E; Schulte-Frohlinde E; Schmid RM; Lersch C
    Oncology; 2005; 69(5):363-71. PubMed ID: 16319507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
    Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma.
    Potti A; Ganti AK; Tendulkar K; Chitajallu S; Sholes K; Koch M; Kargas S
    Anticancer Res; 2003; 23(3B):2671-4. PubMed ID: 12894556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
    Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
    J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of imatinib in unresectable hepatocellular carcinoma.
    Lin AY; Fisher GA; So S; Tang C; Levitt L
    Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of c-kit protooncogene in human hepatocellular carcinoma.
    Chung CY; Yeh KT; Hsu NC; Chang JH; Lin JT; Horng HC; Chang CS
    Cancer Lett; 2005 Jan; 217(2):231-6. PubMed ID: 15617841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of c-kit (CD117) in neuroendocrine tumours--a target for therapy?
    Kostoula V; Khan K; Savage K; Stubbs M; Quaglia A; Dhillon AP; Hochhauser D; Caplin ME
    Oncol Rep; 2005 Apr; 13(4):643-7. PubMed ID: 15756436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B; Tirnitz-Parker JE; Olynyk JK
    Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
    Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
    Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of c-kit+ tumor cells in hepatitis B virus-associated hepatocellular carcinoma.
    Lee ES; Han EM; Kim YS; Shin BK; Kim CH; Kim HK; Won NH; Yeom BW; Kim I; Leong AS
    Am J Clin Pathol; 2005 Jul; 124(1):31-6. PubMed ID: 15923163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells.
    Mansuroglu T; Baumhoer D; Dudas J; Haller F; Cameron S; Lorf T; Füzesi L; Ramadori G
    Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1206-11. PubMed ID: 19491699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
    Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
    Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
    Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD117/KIT expression in pancreatic adenocarcinoma.
    Bateman AC; Judd M; Radenkovic D; Johnson CD
    Pancreas; 2008 Jan; 36(1):76-9. PubMed ID: 18192885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.